AN2 Therapeutics, Inc. ANTX

ANTX Company Overview

AN2 Therapeutics, Inc. (NASDAQ: ANTX) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic infectious diseases with high unmet medical need. The company has primarily concentrated on treatments targeting non-tuberculous mycobacterial (NTM) lung disease, particularly infections caused by Mycobacterium avium complex (MAC). AN2 Therapeutics has operated within the biotechnology and infectious disease therapeutics sectors, with research efforts centered on developing novel anti-infective compounds intended to improve treatment outcomes and reduce limitations associated with existing multidrug regimens.

The company’s lead development candidate was epetraborole, an orally administered investigational therapy originally licensed from Anacor Pharmaceuticals. AN2 Therapeutics positioned itself around the potential for shorter-duration and more tolerable treatment options for difficult-to-treat mycobacterial infections. The company was founded in 2017 and later became publicly traded through an initial public offering in 2022. Public disclosures indicate that following disappointing clinical trial results in late-stage studies involving epetraborole, the company initiated strategic reviews and restructuring efforts. Data regarding long-term operational direction remains limited based on available public sources.